1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Analysis of germline variants in pediatric patients diagnosed with desmoid tumors and nuchal-type fibromas

      brief-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Desmoid tumor (DT) is a fibroblastic proliferation arising in soft tissue characterized by localized infiltrative growth with an inability to metastasize but with a tendency to recurrence. Nuchal-type fibromas are benign soft tissue lesions that are usually developed in the posterior neck. The development of these neoplasms can be associated with a hereditary cancer predisposition syndrome, mainly familial adenomatous polyposis (FAP) syndrome caused by APC germline mutations. Gardner syndrome is a variant of FAP characterized by the presence of extracolonic manifestations including soft tissue tumors as DTs and nuchal-type fibromas. However, the development of these tumors could be associated with germline alterations in other genes related to colorectal cancer development. The objective of this study was to analyze germline variants in APC, MUTYH, POLD1 and POLE genes in five pediatric patients diagnosed with DTs or nuchal-type fibromas. We identified two pathogenic variants in the APC gene in two different patients diagnosed with nuchal-type fibroma and DTs and two variants of uncertain significance in POLD1 in two patients diagnosed with nuchal-type fibroma. Two patients had family history of colorectal cancer, however, only one of them showed an APC germline pathogenic variant. The analysis of germline variants and genetic counseling is essential for pediatric patients diagnosed with DTs or nuchal-type fibromas and their relatives.

          Related collections

          Most cited references43

          • Record: found
          • Abstract: found
          • Article: not found

          Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology

          The American College of Medical Genetics and Genomics (ACMG) previously developed guidance for the interpretation of sequence variants. 1 In the past decade, sequencing technology has evolved rapidly with the advent of high-throughput next generation sequencing. By adopting and leveraging next generation sequencing, clinical laboratories are now performing an ever increasing catalogue of genetic testing spanning genotyping, single genes, gene panels, exomes, genomes, transcriptomes and epigenetic assays for genetic disorders. By virtue of increased complexity, this paradigm shift in genetic testing has been accompanied by new challenges in sequence interpretation. In this context, the ACMG convened a workgroup in 2013 comprised of representatives from the ACMG, the Association for Molecular Pathology (AMP) and the College of American Pathologists (CAP) to revisit and revise the standards and guidelines for the interpretation of sequence variants. The group consisted of clinical laboratory directors and clinicians. This report represents expert opinion of the workgroup with input from ACMG, AMP and CAP stakeholders. These recommendations primarily apply to the breadth of genetic tests used in clinical laboratories including genotyping, single genes, panels, exomes and genomes. This report recommends the use of specific standard terminology: ‘pathogenic’, ‘likely pathogenic’, ‘uncertain significance’, ‘likely benign’, and ‘benign’ to describe variants identified in Mendelian disorders. Moreover, this recommendation describes a process for classification of variants into these five categories based on criteria using typical types of variant evidence (e.g. population data, computational data, functional data, segregation data, etc.). Because of the increased complexity of analysis and interpretation of clinical genetic testing described in this report, the ACMG strongly recommends that clinical molecular genetic testing should be performed in a CLIA-approved laboratory with results interpreted by a board-certified clinical molecular geneticist or molecular genetic pathologist or equivalent.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta.

            Control of stability of beta-catenin is central in the wnt signaling pathway. Here, the protein conductin was found to form a complex with both beta-catenin and the tumor suppressor gene product adenomatous polyposis coli (APC). Conductin induced beta-catenin degradation, whereas mutants of conductin that were deficient in complex formation stabilized beta-catenin. Fragments of APC that contained a conductin-binding domain also blocked beta-catenin degradation. Thus, conductin is a component of the multiprotein complex that directs beta-catenin to degradation and is located downstream of APC. In Xenopus embryos, conductin interfered with wnt-induced axis formation.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found
              Is Open Access

              The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients

              Desmoid tumor (DT; other synonymously used terms: Desmoid-type fibromatosis, aggressive fibromatosis) is a rare and locally aggressive monoclonal, fibroblastic proliferation characterised by a variable and often unpredictable clinical course. Previously surgery was the standard primary treatment modality; however, in recent years a paradigm shift towards a more conservative management has been introduced and an effort to harmonise the strategy amongst clinicians has been made. We present herein an evidence-based, joint global consensus guideline approach to the management of this disease focussing on: molecular genetics, indications for an active treatment, and available systemic therapeutic options. This paper follows a one-day consensus meeting held in Milan, Italy, in June 2018 under the auspices of the European Reference Network for rare solid adult cancers, EURACAN, the European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) as well as Sarcoma Patients EuroNet (SPAEN) and The Desmoid tumour Research Foundation (DTRF). The meeting brought together over 50 adult and pediatric sarcoma experts from different disciplines, patients and patient advocates from Europe, North America and Japan.
                Bookmark

                Author and article information

                Journal
                Transl Pediatr
                Transl Pediatr
                TP
                Translational Pediatrics
                AME Publishing Company
                2224-4336
                2224-4344
                06 September 2023
                18 September 2023
                : 12
                : 9
                : 1715-1724
                Affiliations
                [1 ]Pediatric Oncology Group, Biobizkaia Health Research Institute, Barakaldo , Spain;
                [2 ]Pediatrics Department, Hospital Universitario Cruces, Osakidetza, Barakaldo , Spain;
                [3 ]deptPediatric Department , Universidad del País Vasco UPV/EHU , Leioa, Spain;
                [4 ]Department of Genetics, Cruces University Hospital, Biocruces Bizkaia Health Research Institute, Barakaldo , Spain;
                [5 ]Department of Pathology, Hospital Universitario Cruces, Osakidetza, Barakaldo , Spain
                Author notes
                Correspondence to: Olatz Villate, PhD. Pediatric Oncology Group, Biobizkaia Health Research Institute, Plaza Cruces S/N 48903, Barakaldo, Spain. Email: olatz.villatebejarano@ 123456osakidetza.eus .
                [^]

                ORCID: Piedad Alba-Pavón, 0000-0002-5642-115X; Olatz Villate, 0000-0002-5574-837X.

                Article
                tp-12-09-1715
                10.21037/tp-23-60
                10560355
                37814722
                ee30e599-0733-46bd-b962-67448ad0cd7f
                2023 Translational Pediatrics. All rights reserved.

                Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

                History
                : 02 February 2023
                : 27 July 2023
                Funding
                Funded by: Research Projects from Jesús de Gangoiti Barrera Foundation
                Award ID: Nos. FJGB18/004 and FJGB19/001
                Funded by: La Cuadri del Hospi
                Award ID: No. BC/A/17/008
                Funded by: EITB Media AND BIOEF, SAU
                Award ID: Nos. BIO20/CI/015/BCB and BIO20/CI/011/BCB
                Funded by: the Basque Government Health Department
                Award ID: No. 2021111030
                Categories
                Brief Report

                desmoid tumor (dt),nuchal-type fibroma,germline,next generation sequencing (ngs)

                Comments

                Comment on this article